Warner Chilcott granted approval for acne drug

Jun 24, 2008 (Datamonitor via COMTEX) -- WCRX | Quote | Chart | News | PowerRating -- Warner Chilcott has announced that the FDA has approved a 150mg strength of Doryx delayed-release tablets.

Warner Chilcott's Doryx delayed-release tablets are a tetracycline-class oral antibiotic indicated for adjunctive treatment of severe acne.

Doryx delayed-release tablets contain enteric-coated pellets of doxycycline hyclate which do not release until they reach the small intestine, thereby minimizing the gastrointestinal side effects most commonly associated with other doxycycline products, the company said.

The introduction of the 150mg tablet strength to the existing Doryx delayed-release tablets franchise of 100mg and 75mg offers greater dosing flexibility, said Warner Chilcott. The company will continue to offer Doryx in 75mg and 100mg strengths.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index